TY - JOUR
T1 - Symptom clusters of pain, depressed mood, and fatigue in lung cancer
T2 - Assessing the role of cytokine genes
AU - Reyes-Gibby, Cielito C.
AU - Swartz, Michael D.
AU - Yu, Xiaoying
AU - Wu, Xifeng
AU - Yennurajalingam, Sriram
AU - Anderson, Karen O.
AU - Spitz, Margaret R.
AU - Shete, Sanjay
N1 - Funding Information:
Acknowledgments CA109043, CA128069, CA127219, CA123109, and DE022891 from the National Institutes of Health and is supported in part by the NIH/NCI through MD Anderson’s Cancer Center Support grant CA016672.
PY - 2013/11
Y1 - 2013/11
N2 - Purpose: Symptom clusters, the multiple, co-occurring symptoms experienced by cancer patients, are debilitating and affects quality of life. We assessed if a panel of immune-response genes may underlie the co-occurrence of severe pain, depressed mood, and fatigue and help identify patients with severe versus non-severe symptom clusters. Methods: Symptoms were assessed at presentation, prior to cancer treatment in 599 newly diagnosed lung cancer patients. We applied cluster analyses to determine the patients with severe versus non-severe symptom clusters of pain, depressed mood, and fatigue. Results: Two homogenous clusters were identified. One hundred sixteen patients (19 %) comprised the severe symptom cluster, reporting high intensity of pain, depressed mood, and fatigue and 183 (30 %) patients reported low intensity of these symptoms. Using Bayesian model averaging methodology, we found that of the 55 single nucleotide polymorphisms assessed, an additive effect of mutant alleles in endothelial nitric oxide synthase (-1474 T/A) (posterior probability of inclusion (PPI) = 0.78, odds ratio (OR) = 0.54, 95 % credible interval (CI) = (0.31, 0.93)); IL1B T-31C (PPI = 0.72, OR = 0.55, 95 % CI = (0.31, 0.97)); TNFR2 Met 196Arg (PPI = 0.70, OR = 1.85, 95 % CI = (1.03, 3.36)); PTGS2 exon 10+837T > C (PPI = 0.69, OR = 0.54, 95 % CI = (0.28, 0.99)); and IL10RB Lys47Glu (PPI = 0.68; OR = 1.74; 95 % CI = (1.04, 2.92)) were predictive for symptom clusters. Conclusions: Genetic polymorphisms may facilitate identification of high-risk patients and development of individualized symptom therapies.
AB - Purpose: Symptom clusters, the multiple, co-occurring symptoms experienced by cancer patients, are debilitating and affects quality of life. We assessed if a panel of immune-response genes may underlie the co-occurrence of severe pain, depressed mood, and fatigue and help identify patients with severe versus non-severe symptom clusters. Methods: Symptoms were assessed at presentation, prior to cancer treatment in 599 newly diagnosed lung cancer patients. We applied cluster analyses to determine the patients with severe versus non-severe symptom clusters of pain, depressed mood, and fatigue. Results: Two homogenous clusters were identified. One hundred sixteen patients (19 %) comprised the severe symptom cluster, reporting high intensity of pain, depressed mood, and fatigue and 183 (30 %) patients reported low intensity of these symptoms. Using Bayesian model averaging methodology, we found that of the 55 single nucleotide polymorphisms assessed, an additive effect of mutant alleles in endothelial nitric oxide synthase (-1474 T/A) (posterior probability of inclusion (PPI) = 0.78, odds ratio (OR) = 0.54, 95 % credible interval (CI) = (0.31, 0.93)); IL1B T-31C (PPI = 0.72, OR = 0.55, 95 % CI = (0.31, 0.97)); TNFR2 Met 196Arg (PPI = 0.70, OR = 1.85, 95 % CI = (1.03, 3.36)); PTGS2 exon 10+837T > C (PPI = 0.69, OR = 0.54, 95 % CI = (0.28, 0.99)); and IL10RB Lys47Glu (PPI = 0.68; OR = 1.74; 95 % CI = (1.04, 2.92)) were predictive for symptom clusters. Conclusions: Genetic polymorphisms may facilitate identification of high-risk patients and development of individualized symptom therapies.
KW - Cytokines
KW - Depression
KW - Epidemiology
KW - Fatigue
KW - Genes
KW - Lung cancer
KW - Pain
KW - SNPs
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=84885620506&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885620506&partnerID=8YFLogxK
U2 - 10.1007/s00520-013-1885-5
DO - 10.1007/s00520-013-1885-5
M3 - Article
C2 - 23852407
AN - SCOPUS:84885620506
SN - 0941-4355
VL - 21
SP - 3117
EP - 3125
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 11
ER -